Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced Expiratory Volume After 1 Second (FEV1)-time Profiles of BI 1744 CL 5microg and 10microg (Oral Inhalation, Delivered by the Respimat Inhaler) and Tiotropium Bromide 18microg (Oral Inhalation, Delivered by the HandiHaler) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Next Previous
Trial Profile

Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced Expiratory Volume After 1 Second (FEV1)-time Profiles of BI 1744 CL 5microg and 10microg (Oral Inhalation, Delivered by the Respimat Inhaler) and Tiotropium Bromide 18microg (Oral Inhalation, Delivered by the HandiHaler) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olodaterol (Primary) ; Corticosteroids; Tiotropium bromide; Xanthines
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
  • 09 Sep 2013 Primary endpoint 'AUC-FEV1' has been met.
  • 09 Sep 2013 Results were presented at the European Respiratory Society (ERS) Annual Congress 2013, and were reported in a Boehringer Ingelheim media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top